Yoshiaki Yura published latest article in The Japanese dental science review entitled Presage of oncolytic virotherapy for oral cancer with herpes simplex virus. This article is available in PubMed with an unique identification number PMID: 28479936 and it is published in 2017. The coauthors of this article are Yura Y.
Co-Author(s): Yura, Y
Affiliation(s): Department of Oral and Maxillofacial Surgery II, Osaka University, Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan.
PMID 28479936, Year 2017
Abstract: A virus is a pathogenic organism that causes a number of infectious diseases in humans. The oral cavity is the site at which viruses enter and are excreted from the human body. Herpes simplex virus type 1 (HSV-1) produces the primary infectious disease, gingivostomatitis, and recurrent disease, labial herpes. HSV-1 is one of the most extensively investigated viruses used for cancer therapy. In principle, HSV-1 infects epithelial cells and neuronal cells and exhibits cytotoxicity due to its cytopathic effects on these cells. If the replication of the virus occurs in tumor cells, but not normal cells, the virus may be used as an antitumor agent. Therefore, HSV-1 genes have been modified by genetic engineering, andin vitroandin vivostudies with the oncolytic virus have demonstrated its efficiency against head and neck cancer including oral cancer. The oncolytic abilities of other viruses such as adenovirus and reovirus have also been demonstrated. In clinical trials, HSV-1 is the top runner and is now available for the treatment of patients with advanced melanoma. Thus, melanoma in the oral cavity is the target of oncolytic HSV-1. Oncolytic virotherapy is a hopeful and realistic modality for the treatment of oral cancer.
Journal: The Japanese dental science review